KIDNEY TRANSPLANT AND RESEARCH |
Participation to the study |
More than 1,500,000 people worldwide now live with kidney transplants, and there are thousands of failed transplants every year. Graft rejection is still a constant threat to patients. The consequences are immediate in terms of mortality and morbidity. Current research would reduce the number of rejections through more personalized monitoring and treatment.
Recipient data are collected in two ways. The first type of data concerns the patient's medical history and the medical data collected during the follow-up (blood and urine tests, histopathology of the biopsy, etc.). The second type of data concerns the evaluation of biomarkers of rejection in samples taken specifically for the study: blood proteins and RNA, urinary proteins and biopsy RNA.
Yes, in order for physicians to collect blood or urine samples for research purposes, they must have the prior consent of patients. They must sign a consent form for the biocollection and proposed research.
|
Both. Some data are from the donor and others from the recipient.
No, there is no selection of patients to participate in the study. Patients are adults who have had a kidney transplant. These data are collected at the Nantes University Hospital, the Montpellier University Hospital, the Saint-Louis Hospital and the Necker Hospital in Paris, the Lyon Civil Hospital, the Bordeaux University Hospital and the Toulouse University Hospital.
Patient follow-up in the KTD-innov study begins on the day of transplantation and data/samples are collected during the year following transplantation.
|
|
|
|